Dietary supplementation with D-tagatose in subjects with type 2 diabetes leads to weight loss and raises high-density lipoprotein cholesterol
Dietary supplementation with D-tagatose in subjects with type 2 diabetes leads to weight loss and raises high-density lipoprotein cholesterol
复制标题
DOI：
10.1016/j.nutres.2010.09.007
复制
发表时间：
2010-12-01
影响因子：
4.5
通讯作者：
Zarbalian, Kiarash
中科院分区：
文献类型：
--
作者：
Donner, Thomas W.;Magder, Laurence S.;Zarbalian, Kiarash
口服D-塔格糖（D-tag）减弱患有2型糖尿病（DM）的受试者在口服葡萄糖耐量试验期间血浆葡萄糖的升高，并减少健康人类受试者的食物摄入。喂食塔格糖的大鼠出现摄食量减少和体重增加减少。这项初步研究探讨了每日给予8名2型糖尿病受试者D-标签1年的代谢效应。我们假设该治疗期将导致体重减轻和糖化血红蛋白和脂质谱的改善。2个月的导入期之后是12个月的治疗期，每天3次随食物服用15 g口服D-标签。在12个月的治疗期间没有观察到严重的不良反应。最初招募的12名受试者中有10名出现胃肠道副作用，这些副作用往往是轻度和短暂的。当排除3例患有口服糖尿病的受试者时，在研究期间添加药物和/或增加剂量，平均（SD）体重从108.4（9.0）降至103.3（7.3）kg（P = .001）。糖化血红蛋白从10.6% +/- 1.9%无显著性下降至9.6% +/- 2.3%（P = 0.08）。在研究期间未添加调脂药物的6名受试者中，高密度脂蛋白胆固醇从基线水平30.5 +/- 15.8逐渐升高至第12个月的41.7 +/- 12.1 mg/dL（P <0.001）。在这项初步研究中，体重和高密度脂蛋白胆固醇的显着改善表明，D-标签可能是一个潜在的有用的辅助治疗2型糖尿病患者。(C)2010年爱思唯尔公司All rights reserved.
Oral D-tagatose (D-tag) attenuates the rise in plasma glucose during an oral glucose tolerance test in subjects with type 2 diabetes mellitus (DM) and reduces food intake in healthy human subjects. A reduction in food consumption and less weight gain occur in rats fed tagatose. This pilot study explored the metabolic effects of D-tag given daily to 8 human subjects with type 2 DM for 1 year. We hypothesized that this treatment period would lead to weight loss and improvements in glycated hemoglobin and the lipid profile. A 2-month run-in period was followed by a 12-month treatment period when 15 g of oral D-tag was taken 3 times daily with food. No serious adverse effects were seen during the 12-month treatment period. Ten of the initially12 recruited subjects experienced gastrointestinal side effects that tended to be mild and transient. When 3 subjects were excluded who had oral diabetes, medications added and/or dosages increased during the study and mean (SD) body weight declined from 108.4 (9.0) to 103.3 (7.3) kg (P = .001). Glycated hemoglobin fell nonsignificantly from 10.6% +/- 1.9% to 9.6% +/- 2.3% (P = .08). High-density lipoprotein cholesterol progressively rose from a baseline level of 30.5 +/- 15.8 to 41.7 +/- 12.1 mg/dL at month 12 in the 6 subjects who did not have lipid-modifying medications added during the study (P < .001). Significant improvements in body weight and high-density lipoprotein cholesterol in this pilot study suggest that D-tag may be a potentially useful adjunct in the management of patients with type 2 DM. (C) 2010 Elsevier Inc. All rights reserved.